OSL 12.5% 0.9¢ oncosil medical ltd

OSL Top Pick for FY21, page-14

  1. 437 Posts.
    lightbulb Created with Sketch. 211
    Yes agree, I’m reasonably familiar with the distinctions, ESPAC group in UK has recently presented some results for BR after pre op therapy, they used accepted NCCN criteria to define BR to ensure consistency.
    I think Panco study left it to sites to decide, therefore not standardised. The point of all this is company has made repeated statements that all the patients resected in trial were truly non- resectable, but I think that’s inaccurate.
    they’ve reported R0 before, they say 8 of the 10 resections were R0 but unless they do independent retro review of pre treatment CTs to see who was BR, who was unresectable (by an accepted standard like NCN) it’ll be difficult to answer your question about any R0 in truly unresectable cases. At present company seems to be reporting the entire cohort as unresectable LAPC, no mention of BR anywhere.
 
watchlist Created with Sketch. Add OSL (ASX) to my watchlist
(20min delay)
Last
0.9¢
Change
0.001(12.5%)
Mkt cap ! $30.58M
Open High Low Value Volume
0.8¢ 0.9¢ 0.8¢ $114.3K 13.41M

Buyers (Bids)

No. Vol. Price($)
9 9972750 0.8¢
 

Sellers (Offers)

Price($) Vol. No.
0.9¢ 22973299 19
View Market Depth
Last trade - 16.10pm 18/07/2024 (20 minute delay) ?
OSL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.